Cytosorbents Corp (CTSO) Receives Average Rating of “Buy” from Analysts

Cytosorbents Corp (NASDAQ:CTSO) has earned an average rating of “Buy” from the six ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $10.60.

CTSO has been the subject of several recent analyst reports. B. Riley set a $11.00 price objective on shares of Cytosorbents and gave the stock a “buy” rating in a report on Friday, December 22nd. ValuEngine raised shares of Cytosorbents from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of Cytosorbents in a report on Tuesday, November 21st. Finally, Maxim Group set a $12.00 price objective on shares of Cytosorbents and gave the stock a “buy” rating in a report on Thursday, December 21st.

Shares of Cytosorbents (NASDAQ CTSO) opened at $7.70 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.17 and a current ratio of 3.36. The stock has a market cap of $220.92, a price-to-earnings ratio of -20.26 and a beta of -0.54. Cytosorbents has a 1-year low of $3.30 and a 1-year high of $7.90.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Thursday, November 9th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.07). Cytosorbents had a negative net margin of 67.83% and a negative return on equity of 233.72%. analysts anticipate that Cytosorbents will post -0.26 earnings per share for the current year.

In related news, COO Vincent Capponi sold 4,000 shares of the company’s stock in a transaction on Monday, November 27th. The shares were sold at an average price of $7.00, for a total transaction of $28,000.00. Following the completion of the transaction, the chief operating officer now directly owns 271,062 shares in the company, valued at approximately $1,897,434. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Kathleen P. Bloch sold 12,400 shares of the company’s stock in a transaction on Friday, January 12th. The shares were sold at an average price of $7.75, for a total transaction of $96,100.00. Following the transaction, the chief financial officer now owns 241,038 shares of the company’s stock, valued at $1,868,044.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,800 shares of company stock valued at $360,620. Corporate insiders own 5.60% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Skylands Capital LLC raised its stake in Cytosorbents by 45.1% during the 4th quarter. Skylands Capital LLC now owns 725,608 shares of the medical research company’s stock valued at $4,716,000 after purchasing an additional 225,558 shares during the last quarter. Wealthcare Advisory Partners LLC acquired a new position in Cytosorbents during the 3rd quarter valued at $365,000. Fortaleza Asset Management Inc. raised its stake in Cytosorbents by 81.6% during the 3rd quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock valued at $145,000 after purchasing an additional 10,500 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in Cytosorbents by 145.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock valued at $163,000 after purchasing an additional 22,500 shares during the last quarter. Hedge funds and other institutional investors own 8.65% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/20/cytosorbents-corp-ctso-receives-average-rating-of-buy-from-analysts.html.

Cytosorbents Company Profile

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Analyst Recommendations for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply